Vaccitech’s Immunotherapy Combo With Opdivo Shows Hepatitis B Promise
Searching For A Functional Cure
Executive Summary
The UK company did not profit greatly from its role in COVID-19 vaccine, Vaxzevria, but hopes the same technology can form part of a breakthrough in hepatitis B.
You may also be interested in...
Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate
Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.
Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
Frontline Success Bolsters IO ‘Backbone’ Hopes For GSK’s Jemperli
GSK’s PD-1 inhibitor will not be able to make up much ground on Keytruda, but new studies suggest it is a match for the market-leading PD-1 inhibitors.